Roche Launches AXELIOS 1: A Next-Generation Sequencing Platform That Could Redefine Genomics Research

The future of precision medicine begins with understanding DNA faster, more accurately, and at a lower cost.

That is exactly what Roche aims to achieve with the launch of AXELIOS 1, its next-generation sequencing (NGS) platform powered by the company's proprietary Sequencing by Expansion (SBX) technology.

Announced from Basel, Switzerland, AXELIOS 1 is designed to address some of the biggest challenges in genomics—including sequencing speed, scalability, accuracy, flexibility, and cost efficiency. Roche believes the platform has the potential to reshape genomic research today while laying the foundation for tomorrow's clinical applications in personalized medicine.

Although currently intended for research use only (RUO), AXELIOS 1 represents one of Roche's most significant innovations in molecular diagnostics and genomics in recent years.

For researchers, pharmaceutical companies, biotechnology firms, and healthcare professionals, this launch marks an important milestone in the evolution of DNA sequencing technology.

AXELIOS 1 at a Glance

Why Roche Introduced AXELIOS 1

Over the last decade, DNA sequencing has become central to modern biomedical research.

Scientists now depend on sequencing to:

• Identify disease-causing mutations

• Study cancer genomes

• Track infectious diseases

• Understand rare genetic disorders

• Discover new drug targets

• Develop personalized medicines

However, existing sequencing technologies often force laboratories to compromise between speed, throughput, cost, and flexibility.

Large genomic projects require enormous computing power and infrastructure, while smaller laboratories frequently struggle with expensive equipment and lengthy sequencing workflows.

Roche developed AXELIOS 1 to remove these barriers.

According to the company, the platform combines high accuracy with unprecedented speed and scalability, allowing laboratories to perform everything from small research projects to population-scale genomic studies using a single system.

What Makes AXELIOS 1 Different?

The biggest innovation behind AXELIOS 1 is Roche's proprietary Sequencing by Expansion (SBX) technology.

Unlike conventional sequencing approaches, SBX introduces an entirely new way of reading genetic information.

Instead of sequencing DNA molecules directly, Roche first converts DNA or RNA into specially engineered surrogate polymers known as Xpandomers.

These Xpandomers are approximately 50 times longer than the original genetic molecules.

Why is that important?

Longer molecules produce much clearer electrical signals when passing through nanopores.

This significantly improves:

• Signal clarity

• Sequencing accuracy

• Data quality

• Processing speed

The result is a sequencing workflow capable of delivering high-quality genomic information with near real-time analysis.

Understanding Sequencing by Expansion (SBX)

SBX is one of the most exciting advances in sequencing technology.

The process works in three major stages:

Step 1: DNA or RNA Expansion

The original nucleic acid sequence is converted into an expanded polymer called an Xpandomer.

Rather than reading the original molecule directly, Roche creates an enlarged version that is easier to interpret.

Step 2: Nanopore Detection

The expanded Xpandomers pass through millions of nanopores embedded within a reusable CMOS sensor.

As each molecule passes through the nanopore, unique electrical signals are generated.

Step 3: AI-Powered Analysis

Sophisticated computational algorithms rapidly decode these electrical signals into genetic sequence information.

The platform performs base calling and variant analysis almost in real time.

Together, these innovations allow researchers to obtain highly accurate sequencing data faster than traditional workflows.

Why Speed Matters in Genomics

Genomic sequencing projects often generate enormous volumes of data.

Traditional workflows may require:

• Sample preparation

• Library construction

• Sequencing

• Base calling

• Bioinformatics analysis

• Variant identification

Each stage can add hours—or even days—to the research process.

AXELIOS 1 aims to dramatically shorten these timelines.

According to Roche, the platform can generate whole-genome sequencing results within the same day, enabling researchers to make faster scientific decisions and accelerate discovery.

Designed for Every Laboratory

One of AXELIOS 1's biggest strengths is flexibility.

Many sequencing systems are optimized either for:

• High-throughput genomic centers

or

• Small laboratory studies

Rarely both.

AXELIOS 1 has been designed to handle:

• Small research batches

• Medium-sized sequencing projects

• Large population genomics studies

without requiring laboratories to change platforms or workflows.

This flexibility allows institutions to scale research efficiently as project requirements evolve.

A Platform Built for Modern Genomics

The platform supports numerous sequencing applications, including:

Whole Genome Sequencing (WGS)

Comprehensive analysis of an individual's complete genetic code.

Whole Exome Sequencing (WES)

Focused sequencing of protein-coding regions linked to many inherited diseases.

RNA Sequencing

Studying gene expression and transcriptomics.

Single-Cell Sequencing

Understanding how individual cells behave differently within tissues.

Spatial Genomics

Mapping gene activity while preserving tissue architecture.

DNA Methylation Analysis

Investigating epigenetic modifications that influence disease development.

These capabilities make AXELIOS 1 suitable for research across multiple scientific disciplines.

Partnerships Strengthening the Platform

Rather than building an isolated ecosystem, Roche has collaborated with leading genomics organizations.

Key collaborations include:

Hartwig Medical Foundation

Supporting validation of large-scale genomic applications.

Broad Clinical Labs

Evaluating real-world sequencing performance.

10x Genomics

Developing single-cell and spatial sequencing workflows.

Google DeepVariant

Providing advanced variant-calling support.

XOOS Open-Source Bioinformatics Suite

Offering researchers flexible data analysis tools without proprietary restrictions.

These collaborations help ensure that researchers can integrate AXELIOS 1 into existing genomic workflows.

Record-Breaking Sequencing Performance

Since unveiling SBX technology in 2025, Roche has reported multiple proof-of-concept studies demonstrating applications across:

• Oncology

• Infectious diseases

• Human genetics

• RNA sequencing

• Methylation analysis

• Single-cell genomics

• Whole genome sequencing

According to Roche, early-access users also demonstrated what the company describes as the world's fastest DNA sequencing technique, highlighting the platform's ability to process genomic data at unprecedented speed.

Why Cost Efficiency Matters

Genome sequencing has become significantly less expensive over the past decade.

Yet large-scale sequencing projects still involve considerable costs related to:

• Instruments

• Reagents

• Data storage

• Bioinformatics

• Computing infrastructure

AXELIOS 1 seeks to reduce these barriers through:

• Reusable CMOS sensors

• Flexible sequencing workflows

• High-throughput architecture

• Open-source analysis software

• Scalable laboratory operations

Lower sequencing costs could make genomic research more accessible to academic institutions, hospitals, biotech startups, and pharmaceutical companies.

The Growing Sequencing Market

The global sequencing market is expanding rapidly.

According to Roche, the sequencing industry is currently valued at approximately US$7.3 billion, with double-digit growth expected over the coming years.

Several trends are driving this expansion:

• Precision medicine

• Oncology research

• Rare disease diagnostics

• Pharmacogenomics

• Population genomics

• AI-driven drug discovery

• Personalized healthcare

• Infectious disease surveillance

As demand increases, next-generation sequencing platforms capable of balancing speed, scalability, and affordability will become increasingly important.

Implications for Drug Discovery

Modern pharmaceutical research depends heavily on genomic data.

Sequencing enables researchers to:

• Discover new therapeutic targets

• Understand disease biology

• Identify biomarkers

• Develop companion diagnostics

• Select patients for clinical trials

• Monitor treatment response

By accelerating sequencing workflows, AXELIOS 1 could help pharmaceutical companies shorten early-stage research timelines and improve decision-making during drug discovery.

What This Means for Precision Medicine

Healthcare is steadily moving toward personalized treatment strategies.

Instead of treating every patient the same way, physicians increasingly use genomic information to guide:

• Cancer therapies

• Rare disease diagnosis

• Pharmacogenomics

• Gene therapy

• Biomarker-driven medicine

Although AXELIOS 1 is currently intended for research use only, Roche believes the underlying SBX technology has the potential to support future clinical applications.

If successfully translated into diagnostics, faster sequencing could eventually help clinicians make more timely treatment decisions.

Career Opportunities Emerging from Genomics Innovation

Advances in sequencing technology are creating strong demand for professionals across life sciences and biotechnology.

Growing career opportunities include:

• Genomics Scientist

• Bioinformatics Analyst

• Molecular Biologist

• Clinical Genomics Specialist

• Computational Biologist

• NGS Application Scientist

• Data Scientist – Genomics

• Medical Affairs Specialist

• Regulatory Affairs Professional

• Clinical Research Associate

• AI in Drug Discovery Specialist

• Molecular Diagnostics Scientist

As genomics becomes increasingly integrated into healthcare and pharmaceutical R&D, demand for these specialized skills is expected to continue growing globally.

Challenges Ahead

Despite its promising capabilities, widespread adoption of new sequencing technologies depends on several factors:

• Independent validation by the scientific community

• Integration into existing laboratory workflows

• Cost of implementation

• Data management infrastructure

• Regulatory pathways for future clinical applications

• User training and technical support

Like any new platform, AXELIOS 1 will need to demonstrate consistent performance across diverse research settings over time.

The Future of DNA Sequencing

Sequencing technology has evolved dramatically over the past two decades—from the Human Genome Project to portable nanopore sequencers and AI-assisted genomics.

AXELIOS 1 represents the next chapter in that journey.

By combining innovative SBX chemistry, reusable sensor technology, scalable architecture, and open-source bioinformatics, Roche is positioning itself at the forefront of next-generation sequencing.

Whether it ultimately transforms clinical diagnostics remains to be seen, but its potential impact on biomedical research, drug discovery, and precision medicine is already generating significant interest across the global scientific community.

Key Takeaways

• Roche has launched AXELIOS 1, a next-generation sequencing platform powered by proprietary Sequencing by Expansion (SBX) technology.

• The platform is designed for research use only and supports applications including whole genome sequencing, RNA sequencing, single-cell analysis, spatial genomics, and methylation studies.

• SBX technology converts DNA or RNA into Xpandomers, enabling clearer signals, higher accuracy, and faster sequencing.

• AXELIOS 1 offers high throughput, scalability, flexibility, and near real-time genomic analysis.

• Roche has partnered with organizations including 10x Genomics, Broad Clinical Labs, Hartwig Medical Foundation, and Google DeepVariant to strengthen the platform ecosystem.

• The global sequencing market is valued at US$7.3 billion and is expected to grow at double-digit rates in the coming years.

• Advances in sequencing technology are expected to accelerate drug discovery, genomics research, and personalized medicine while creating new career opportunities in biotechnology and pharmaceutical R&D.

Why This Matters for Pharma Professionals

At BIG PHARMA JOBS, we track major innovations like Roche's AXELIOS 1 because they shape the future of pharmaceutical research and hiring.

As next-generation sequencing becomes faster, more scalable, and increasingly integrated with AI, the demand for professionals in genomics, molecular biology, bioinformatics, clinical research, diagnostics, and precision medicine will continue to rise.

For researchers, biotech professionals, and pharma job seekers, staying informed about technologies such as SBX sequencing isn't just about following industry news—it's about preparing for the next wave of opportunities in life sciences and healthcare innovation.